Updated: Updated Zanamivir powder treatments for influenza guidance.
These patient group direction (PGD) templates support the supply of:
oseltamivir 75mg and 30mg capsules for post exposure prophylaxis (PEP) of influenza zanamivir inhalation powder for PEP of influenza oseltamivir 75mg and 30mg capsules for the treatment of influenza zanamivir inhalation powder for the treatment of influenzaThey all apply to adult residents/users and staff of care facilities (with or without nursing) and are valid from 26 July 2018 until 26 July 2021.
The PGD templates require further authorisation by a clinical governance or patient safety lead, who has designated responsibility for signing PGDs, so the documents meet legal requirements for a PGD. The PGDs are not legal or valid without this local, formal authorisation.
Adoption and governance of the use of these PGDs is the responsibility of the authorising commissioning body and providers.
Provider organisations and health professionals should check they are working to the current PGD versions and only work to a legally authorised PGD from their commissioning body.
Local copy of 20180605PHEPGDOseltamivirProphylaxisv03.00.docx
Local copy of 20190118PHEPGDZanamivirProphylaxisv03.00__14_.docx
Local copy of 20180605PHEPGDOseltamivirTreatment_v03.00.docx
Local copy of 20190118PHEPGDZanamivirTreatmentv03.00__1_.docx seen at 14:33, 23 February in Publications on GOV.UK.
Email this to a friend.